Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and its incidence is still increasing. While the primary curative treatment for HCC is surgical resection, a major obstacle for the treatment of HCC is the high frequency of tumor recurrence even after curative resection...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology 2011-03, Vol.46 (3), p.289-296
Main Authors: Tanaka, Shinji, Arii, Shigeki
Format: Article
Language:English
Subjects:
Abdominal Surgery
Angiogenesis Inhibitors - therapeutic use
Antimitotic agents
Antineoplastic agents
Cancer
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - pathology
Cell Cycle - drug effects
Chemotherapy
Colorectal Surgery
Gastroenterology
Hepatology
Hepatoma
Humans
Hypoxia
Liver Neoplasms - drug therapy
Liver Neoplasms - pathology
Medical colleges
Medicine
Medicine & Public Health
Molecular Targeted Therapy
Neoplasm Invasiveness
Neoplasm Metastasis
Neoplastic Stem Cells
Review
Signal Transduction - drug effects
Stem Cell Niche
Surgical Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and its incidence is still increasing. While the primary curative treatment for HCC is surgical resection, a major obstacle for the treatment of HCC is the high frequency of tumor recurrence even after curative resection. Effective palliative treatment is hindered by the evidence that HCC is frequently resistant to conventional chemotherapy and radiotherapy. Targeted therapy which specifically inhibits molecular abnormalities has emerged as a novel approach for the innovative and effective medical treatment of malignancies. In order to fulfill this promise there is an urgent need to identify the optimal targets for the treatment of HCC. A multi-kinase angiogenesis inhibitor, sorafenib, has been revealed as the first agent to show favorable overall survival in patients with advanced HCC. A new era of HCC treatment has arrived, but there has been limited improvement in survival benefits with the status quo. This review summarizes molecular targeted therapy for HCC, with a focus on angiogenesis, growth signaling, and mitosis, as well as a promising concept, “cancer stemness” for the current and potential next strategies of HCC treatment.
ISSN:0944-1174
1435-5922
DOI:10.1007/s00535-011-0387-9